Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis

Published:2021-01 Issue:1 Volume:59 Page:99-105
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Uchida Yoshinori,Ikeda Satoshi^ORCID,Sekine Akimasa,katano Takuma,Tabata Erina,Oda Tsuneyuki,Okuda Ryo,Kitamura Hideya,Baba Tomohisa,Komatsu Shigeru,Ogura Takashi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference16 articles.

1. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline;Raghu;Am J Respir Crit Care Med,2015

2. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis;Richeldi;N Engl J Med,2014

3. Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study;Abe;Drug Des Dev Ther,2018

4. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions;Galli;Respirology,2017

5. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres;Toellner;Clin Transl Med,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-07-04

2. Outcome after nintedanib therapy for fibrosing interstitial lung disease in patients without dyspnea;2024-06-25

3. Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis;PLOS ONE;2024-06-13

4. Pneumopathies interstitielles diffuses à travers les âges;Revue des Maladies Respiratoires Actualités;2024-06

5. Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib;Respiratory Investigation;2024-05